We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down
Read MoreHide Full Article
Shares of Puma Biotechnology, Inc. (PBYI - Free Report) tumbled almost 27% as the chances of its breast cancer treatment drug Nerlynx (neratinib) getting approval in Europe this year look dim.
However, Puma’s shares have significantly outperformed the industryso over a year. The stock has rallied 178.4% compared with the industry’s 8.9% growth.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency met with the company to convey that the former will most probably vote against the approval of neratinib at the formal CHMP decision vote scheduled next month. According to CHMP, the benefit risk assessment is unfavorable because the study results are based on evidence from a single pivotal trial.
The company might need to take additional steps in order to get approval in Europe.
The company filed a MAA for neratinib in Europe in June 2016. Neratinib is being evaluated for the extended adjuvant treatment of early stage HER2-positive breast cancer that has previously been treated with a trastuzumab containing regimen.
The CHMP’s opinion was based on the results from both the phase III ExteNET trial in extended adjuvant early stage HER2-positive breast cancer and the phase II CONTROL trial in extended adjuvant early stage HER2-positive breast cancer.
We remind investors that Nerlynx received an FDA approval in July 2017 for the extended adjuvant treatment of patients with early-stage HER2 over expressed/amplified breast cancer, who have been previously treated with Roche's (RHHBY - Free Report) Herceptin-based adjuvant therapy. Notably, Nerlynx is the first anti-HER2 treatment to be approved by an extended adjuvant therapy for the indication. In the third quarter of 2017, the company generated net revenue from initial sales of NERLYNX of approximately $6.1 million.
In November 2017, Puma inked an exclusive licensing agreement with Specialised Therapeutics Asia, a Singapore-based biopharmaceutical company, to commercialize Nerlynx in Australia, New Zealand and South East Asia. The company expects a regulatory approval for Nerlynx in Australia by the second quarter of 2019.
Exelixis’ earnings per share estimates have moved up from 72 cents to 73 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in the last four quarters, with an average beat of 572.92%. Share price of the company surged 64.1% over a year.
XOMA’s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 in the last 60 days. The company delivered a positive earnings surprise in one of the last four quarters, with an average beat of 47.92%. Share price of the company skyrocketed 634.7% over a year.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down
Shares of Puma Biotechnology, Inc. (PBYI - Free Report) tumbled almost 27% as the chances of its breast cancer treatment drug Nerlynx (neratinib) getting approval in Europe this year look dim.
However, Puma’s shares have significantly outperformed the industry so over a year. The stock has rallied 178.4% compared with the industry’s 8.9% growth.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency met with the company to convey that the former will most probably vote against the approval of neratinib at the formal CHMP decision vote scheduled next month. According to CHMP, the benefit risk assessment is unfavorable because the study results are based on evidence from a single pivotal trial.
The company might need to take additional steps in order to get approval in Europe.
The company filed a MAA for neratinib in Europe in June 2016. Neratinib is being evaluated for the extended adjuvant treatment of early stage HER2-positive breast cancer that has previously been treated with a trastuzumab containing regimen.
The CHMP’s opinion was based on the results from both the phase III ExteNET trial in extended adjuvant early stage HER2-positive breast cancer and the phase II CONTROL trial in extended adjuvant early stage HER2-positive breast cancer.
We remind investors that Nerlynx received an FDA approval in July 2017 for the extended adjuvant treatment of patients with early-stage HER2 over expressed/amplified breast cancer, who have been previously treated with Roche's (RHHBY - Free Report) Herceptin-based adjuvant therapy. Notably, Nerlynx is the first anti-HER2 treatment to be approved by an extended adjuvant therapy for the indication. In the third quarter of 2017, the company generated net revenue from initial sales of NERLYNX of approximately $6.1 million.
In November 2017, Puma inked an exclusive licensing agreement with Specialised Therapeutics Asia, a Singapore-based biopharmaceutical company, to commercialize Nerlynx in Australia, New Zealand and South East Asia. The company expects a regulatory approval for Nerlynx in Australia by the second quarter of 2019.
Puma Biotechnology Inc Price
Puma Biotechnology Inc Price | Puma Biotechnology Inc Quote
Zacks Rank & Key Picks
Puma carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the health care space are Exelixis, Inc. (EXEL - Free Report) and XOMA Corporation (XOMA - Free Report) . While Exelixis sports a a Zacks Rank #1 (Strong Buy), XOMA carries a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Exelixis’ earnings per share estimates have moved up from 72 cents to 73 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in the last four quarters, with an average beat of 572.92%. Share price of the company surged 64.1% over a year.
XOMA’s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 in the last 60 days. The company delivered a positive earnings surprise in one of the last four quarters, with an average beat of 47.92%. Share price of the company skyrocketed 634.7% over a year.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>